In recognition of Healthy Aging Month, Bausch + Lomb has released new Canadian survey findings highlighting significant gaps in the diagnosis and management of dry eye disease, a condition that becomes increasingly common with age. According to the press release, dry eye prevalence is highest among adults over 55 years old.
The survey, conducted between March and April 2026 among 481 Canadian adults who currently use or have used prescription dry eye treatments, reveals that many patients struggle to access timely care and appropriate treatment pathways.
Diagnosis delays and unmet patient needs
The findings show that Canadians with dry eye disease often face a long and fragmented path to diagnosis. According to the report, patients typically see two or more healthcare professionals before receiving a diagnosis, indicating that dry eye is rarely identified at the first point of care.
The survey also highlights strong patient demand for earlier access to prescription therapies. Four in five patients wish they had started prescription treatment sooner, and nearly half of respondents over age 56 were unaware that prescription options exist.
Dr. François Piuze, creator of Quebec’s Dry Eye Symposium, notes: “Dry eye disease becomes increasingly common as we age, but it should never be dismissed as simply a normal part of aging.” He emphasizes that early recognition and conversations with eye care professionals can help patients better understand their symptoms and treatment options.
Inflammation: a key concern for patients
More than 70% of respondents consider treating inflammation essential, underscoring the importance of addressing the underlying cause of dry eye disease rather than relying solely on lubricants.
Dr. Evelyn Lo, past president of BC Doctors of Optometry, adds that the findings reinforce the need for earlier diagnosis, clearer patient education, and timely escalation beyond over‑the‑counter lubricants when clinically appropriate.
Barriers to access for older Canadians
The survey also points to challenges in treatment accessibility. Older patients often face insurance coverage obstacles, making it harder to obtain prescription therapies. Bausch + Lomb states that it is working to reduce these barriers through patient support programs and reimbursement solutions, helping Canadians “see better, live better, and maintain their independence.”
Dry eye and aging: what Canadians should know
Dry eye disease can be triggered by multiple age‑related factors, including medications, hormonal changes, environment, and underlying health conditions. Symptoms include dryness, irritation, burning and blurred vision. Evidence increasingly shows that inflammation plays a central role in the development and progression of dry eye disease.
Artificial intelligence (AI) has been widely discussed in recent years, but its impact on Canadian eye care is now tangible. From personalized dry eye management to automated retinal screening and advanced OCT biomarker analysis, AI-driven platforms are helping clinics improve efficiency, standardize documentation, and strengthen diagnostic support.
Not all AI tools serve the same function. Some operate as screening and triage systems, others deliver quantitative imaging analytics, and some provide broader clinical decision-support resources. Below is an overview of six AI-enabled tools currently shaping clinical conversations in Canadian eye care.
1: CSI Dry Eye Software -Standardizing Dry Eye Care
Dry eye disease remains one of the most common conditions encountered in primary eye care. CSI Dry Eye Software is a cloud based clinical management platform designed to structure and streamline dry eye assessment and management. Using AI-driven algorithms, the platform synthesizes patient questionnaires, diagnostic testing, and clinical findings. It identifies likely contributing mechanisms—such as evaporative or aqueous deficient components—and generates structured, individualized treatment plans.
Key capabilities include:
Analysis of multiple dry eye tests, patient questionnaires, and clinical data to identify underlying causes and contributing factors.
Support for personalized, protocol-driven treatment plans by comparing patient data against databases of OTC products, prescription therapies, and in-office procedures.
Longitudinal tracking of patient progress across multiple visits.
Cloud-based access (SaaS) with structured dashboards, automated reminders, customized reporting, and follow-up tools to streamline workflow.
Reduced chair time and decreased subjective variability through standardized analysis and treatment guidance.
Integration considerations: CSI operates as a browser-based SaaS platform and does not require proprietary hardware. It works with most dry eye data already collected in clinic. EMR integration varies by system; summaries can typically be exported or incorporated into records.
Best suited for: Clinics seeking structured, protocol-driven dry eye management
2: OphtAI – Automated Retinal Screening
OphtAI is designed for automated analysis of colour fundus photography. It screens for diabetic retinopathy, glaucoma, and age related macular degeneration (AMD), generating real-time reports with lesion mapping, severity grading, and confidence scoring.
Key features include:
Detection of major retinal diseases from fundus photographs.
Real-time analysis with downloadable PDF reports detailing lesion mapping and severity grading.
Flexible access via web portal, mobile application, or API.
Designed for rapid, automated screening in tele-ophthalmology or population-based programs.
Integration considerations: The platform is accessible via web, mobile, or API. In Canada, it is also currently integrated with Tecksoft EyeVu EMR. It does not require proprietary imaging hardware beyond a compatible fundus camera.
Best suited for: Primary care environments and large-scale screening programs.
3: Altris AI – OCT Biomarker Quantification
Altris AI focuses on AI-enhanced interpretation of OCT scans. The platform detects and quantifies more than 70 retinal pathologies and biomarkers, including drusen subtypes, fluid, atrophy, and edema. It is particularly positioned for monitoring AMD, in both dry and neovascular forms.
Core features include:
Automated detection and quantification of 70+ retinal biomarkers and pathologies.
Highlighting and longitudinal tracking of AMD-related features to support monitoring of progression and treatment response.
Conversion of raw OCT data into structured, reproducible outputs, including heatmaps, Early Treatment Diabetic Retinopathy Study (ETDRS) grid visualizations, graphs, and quantitative measurements.
Support for research workflows through longitudinal comparisons and advanced analytics.
Integration considerations: Altris AI offers cloud-based access as standard, with on-premise options available. It is vendor-neutral and designed to integrate into existing OCT workflows, compatible with devices from multiple major manufacturers.
Best suited for: Retina-focused practices and imaging centres requiring detailed OCT analytics.
4: AI4Eyes – Ocular Surface Test Consolidation
AI4Eyes is a Canadian-developed platform that combines proprietary hardware with AI-driven diagnostic software. The tool consolidates approximately 10 anterior segment tests into a streamlined, AI-guided imaging workflow. Clinicians receive AI supported diagnostic suggestions and treatment recommendations for review.
Notable capabilities:
Consolidation of multiple anterior segment tests into a single AI-guided workflow.
Machine learning–based analysis of ocular surface parameters.
Personalized treatment suggestions that clinicians can validate and refine.
Integration considerations:AI4Eyes integrates into the pre-test workflow and supplements existing diagnostic data collection. Unlike pure SaaS platforms, it requires acquisition of dedicated hardware.
Best suited for: Practices investing in integrated anterior segment and dry eye diagnostics.
5: VisualDx – Broad Clinical Decision Support
VisualDx is a clinical decision-support platform rather than a dedicated eyecare AI tool. It contains a database of more than 45,000 medical images and peer-reviewed clinical content. Clinicians can input signs and symptoms to generate differential diagnoses—particularly valuable when ocular findings intersect with dermatologic or systemic disease.
Access to treatment guidance, ICD coding support, and complication alerts.
Patient education tools to facilitate communication and shared decision-making.
Integration considerations:VisualDx is web-based and accessible via browser or app, with API integration options available.
Best suited for: Clinicians managing complex or multi-system presentations.
6: OCTolyzer – Open-Source OCT Research
OCTolyzer occupies a distinct niche as an open-source OCT analysis toolkit developed for research use. In Canada, it may be used in research environments but is not intended for direct patient diagnosis. The platform performs automated retinal and choroidal segmentation and extracts quantitative metrics such as thickness measurements and vascular indices.
Integration considerations: OCTolyzer runs on standard computing systems and is platform-agnostic. It is not a regulated clinical diagnostic device and is intended for academic research, validation studies, and AI development.
Best suited for: Universities, research laboratories, and AI development teams.
In Summary
AI adoption in Canadian eye care continues to accelerate, with tools serving diverse clinical objectives:
OCTolyzer advances academic research and innovation.
Selecting the appropriate platform depends on clinical focus, practice size, patient volume, regulatory considerations, and readiness to integrate new technologies into established workflows. As AI continues to evolve, its role in Canadian optometry is shifting from experimental to operational—reshaping how optometrists assess, document, and manage ocular disease.
About the Author:
Maryam Moharib, BOptom, BHSc, CSPO, CAPM
Maryam Moharib, BOptom, BHSc, CSPO, CAPM, is an optometrist and certified product owner with expertise in EMR implementation and clinic workflow optimization. She brings years of clinical and project management experience bridging technology and patient care.
Want to see more articles like this? Click here to subscribe to our FREE print magazine and newsletters!
Created by the pediatric experts behind the trusted Dilli Dalli brand, Demi + Dash delivers fashionable eyewear solutions for style-conscious kids ages 7–12. The collection features contemporary styling while still providing fit, flexibility and performance that parents and ECPs expect.
Centennial Optical is a Canadian company distributing ophthalmic frames and lenses, sunglasses, lab supplies, cases and accessories, nationally and internationally. Founded in 1967, Centennial sells optical goods and services to Eye Care Professionals, optical laboratories and optical retailers. Centennial is fully licensed by Health Canada to sell Class I medical devices. With corporate headquarters and central distribution located in Toronto, Centennial also has local customer service in Montreal and Vancouver.
Centennial Optical is a sponsor and supplier of exclusive products to members of the Canadian Association of Optometrists. Centennial Optical is also a member of The Vision Council, an international association representing suppliers of vision care products and services.
Eyewear (Frames)
Centennial Optical began as a distributor of ophthalmic frames, selling its own exclusive brands. Today, in addition to being the Canadian distributor for several international designer brands of eyewear, such as Ann Taylor, BCBG MAXAZRIA, Champion, Christian Lacroix, Hackett, London Fog, Jones New York, Nicole Miller, Paradigm, TLG, Vera Wang and 2BB. Centennial works closely in developing and bringing to market the indigenous brand IO:KEN as well as Canadian fashion icons Alfred Sung, Roots and Beaver Canoe.
Lenses and Lab Supplies
Centennial is the Canadian wholesale distributor for HOYA, Rodenstock and Kodak Lenses, plus other ophthalmic lenses from Signet Armorlite, Vision Ease, and lens products from a number of other manufacturers. Centennial’s house lens brands, CHOICE and Centoptic, offer customers an exceptional combination of performance and value in a wide selection of materials and treatments. Centennial is also pleased to offer a full range of lab supplies from 3M, BPI, DAC Vision and other suppliers.
Sunwear
Centennial is proud to distribute ROOTS, Serengeti, Bollé, and REVO Sunwear, both plano and Rx, to Canadian ECPs. As the maker of the world’s finest driving sunglasses, Serengeti utilizes only the latest technologies and premium materials. Bollé constantly refines their trademark combination of fit, fashion and comfort, for high-quality performance and protection. REVO sunglasses blend sleek design, tailored fit and legendary lens protection.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e- newsletters!
Etnia Eyewear Culture has appointed Massimo Vian as CEO, marking the beginning of a new phase focused on accelerating the national and international growth of its portfolio of brands. In his new role, Vian will oversee the executive management of the group — which includes Etnia Barcelona, lool, Pellicer, Moi Aussi, and The Readers — and lead the implementation of the company’s global strategy. Etnia Barcelona remains one of Europe’s best‑selling eyewear brands, while lool is among the group’s fastest‑growing labels.
As part of the company’s expansion strategy, the B2B channel, driven by independent opticians, will continue to play a central role, remaining one of Etnia Eyewear Culture’s key assets.
The appointment comes 25 years after the creation of Etnia Barcelona, the group’s flagship brand, and reflects the ambition to elevate the company’s international presence and accelerate its growth trajectory. In this new phase, David Pellicer, founder and owner of Etnia Eyewear Culture, assumes the role of Executive Chairman. Pellicer will remain actively involved, guiding long‑term strategic direction and overseeing the creative identity of the brands. The goal is to preserve the independent spirit and artistic DNA that have defined Etnia Eyewear Culture while strengthening the organizational capabilities needed for global expansion.
According to Pellicer, “the addition of Massimo Vian is a significant step for Etnia Eyewear Culture, as he will help us take the necessary steps to accelerate our growth and consolidation at an international level. An objective in which the rest of the team will also play a key role.”
A global career in eyewear and fashion
Massimo Vian brings more than two decades of international experience in the eyewear and fashion industries. His career includes executive roles at Gucci, Prada, and Falconeri, as well as a 13‑year tenure at Luxottica, where he developed a comprehensive vision of the global eyewear market.
For Vian, “Etnia Barcelona is a unique brand with a highly talented team and enormous potential. The company has a strong foundation and now the challenge is to grow by strengthening the organization and its execution capabilities, without losing the DNA that makes it unique: its distinctive approach to luxury through quality, color, and art.”
A new survey released by Bausch + Lomb reveals that dry eye disease remains one of the least recognized symptoms associated with perimenopause and menopause. According to the press release, “only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom,” compared with 79% who identify hot flashes.
The findings underscore a significant gap in awareness: 78% of women were surprised to learn that dry eye can be linked to perimenopause or menopause. This lack of recognition may delay care and contribute to worsening symptoms.
Dry eye symptoms affect daily activities
Hormonal changes during perimenopause and menopause can influence tear production, tear quality and tear evaporation, leading to symptoms such as burning, irritation, fluctuating vision and discomfort. Among women who experience dry eye during these stages, 80% said the symptom came as a surprise.
The survey also highlights the impact on daily life. Women experiencing dry eye during perimenopause, menopause or post-menopause reported:
58% difficulty reading
53% difficulty using screens
26% difficulty driving
17% reduced productivity
These findings illustrate how dry eye can interfere with routine activities and overall quality of life.
Women report challenges navigating menopause
Beyond dry eye, many women expressed difficulty managing menopause-related symptoms. More than 43% said the process feels overwhelming, and over 40% reported not knowing where to begin when seeking support or treatment.
Mayssa Attar, Ph.D., senior vice president of Consumer and Pharmaceutical R&D at Bausch + Lomb, notes: “Dry eye symptoms can have a meaningful impact on everyday activities and quality of life, yet they are often not associated with perimenopause and menopause.” She emphasizes the importance of encouraging women to speak with eye care professionals when symptoms arise.
Dr. Neda Gioia, OD, CNS, IFMCP, adds that these findings are a reminder that eye health should be part of the menopause conversation, and that early recognition can help women explore management options that improve comfort and daily functioning.
Supporting women’s eye health
Bausch + Lomb offers a broad portfolio of solutions for dry eye management, including nutritional supplements, over-the-counter drops, prescription treatments and diagnostic technologies. The company states it remains committed to advancing education and awareness to help women better understand and manage dry eye symptoms during perimenopause and menopause.
For more information on dry eye symptoms, risk factors and available treatment options, visit KnowYourDryEye.com.
Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.
ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.
Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.
CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.
Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.
ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.
Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.
CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.
Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.
ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.
Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.
CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.
Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.
ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.
Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.
CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.
